Background: Neuromyelitis optica (NMO) is a severe autoimmune disease targeting optic nerves and spinal cord. The monoclonal anti-CD20 B-cell antibody rituximab is an emerging therapeutic option in NMO. However, neither long-term efficacy or safety of rituximab, nor the correlation between B-cell counts, B-cell fostering cytokines, aquaporin-4 antibodies (AQP4-ab), and disease activity in NMO, have been investigated prospectively.
Neuromyelitis optica (NMO) is a severe demyelinating inflammatory disease of the CNS characterized by recurrent optic neuritis and episodic myelitis. [1] [2] [3] There is evidence that aquaporin-4 antibodies (AQP4-ab) contribute to disease pathogenesis. 4, 5 However, while AQP4-ab titer was associated with clinical course in one study, 6 others could not detect such correlation. 7 Treatment of NMO usually includes immunosuppressant medication. However, controlled clinical trials are lacking, and patients with NMO often experience ongoing disease activity. During the past few years the B-cell-depleting monoclonal anti-CD20 antibody rituximab has been used for treatment of autoimmune diseases. [7] [8] [9] However, data on NMO are limited to small retrospective case series, 10 and no data exist on repeated or long-term treatment. Additionally, there is no consensus on the exact time schedule of rituximab reapplication. Further, the potential role of laboratory markers, including AQP4-ab titers, B-cell counts, and levels of B-cell-fostering cytokines, has not been investigated prospectively. We thus performed a prospective long-term observation of 10 patients with NMO who were treated with rituximab up to 5 times.
METHODS Patients and treatment. Ten patients with definite NMO 11 who had previously failed to respond to at least one standard immunotherapy were treated with rituximab (table 1). One course consisted of a total of 2 g rituximab IV divided into 2 biweekly infusions, 12 preceded by premedication (100 mg prednisolone, 1 g acetaminophen, 4 mg dimethindene). Initially, . Immunosuppression with azathioprine, methotrexate (MTX), or mitoxantrone led to moderate stabilization, whereas no effect or worsening occurred when patients were treated with interferon-␤ or IV immunoglobulin (IVIg). In some patients treatment duration was too short to allow conclusions on efficacy. In such patients, the annual relapse rate was not determined (ND). Patient 1 died after the first rituximab and is not listed. b Three courses of mitoxantrone were given with monthly intervals; the patient was free of relapses for 1 year thereafter.
the second course was given after reappearance of B cells, but later it was applied at fixed time intervals every 6 -9 months. Patients were examined every 3 months.
Standard protocol approvals, registrations, and patient consents. Patients gave written informed consent before the first treatment with rituximab. The study was approved by the local institutional review board.
Laboratory assessments. Blood was drawn before therapy and then every 3 months. Sera were stored at Ϫ80°C and analyzed within the same assay for AQP4-ab, BAFF, APRIL, and immunoglobulin (Ig) isotypes (IgG, IgM, IgA).
B-cell counts. Lymphocyte subsets were determined by flow cytometry (FC) in freshly obtained blood samples. B-cell depletion was defined as counts below 0.01 ϫ 10 9 /L.
AQP4 antibody assay.
A cell-based FC assay was used for quantification of AQP4 antibodies as reported previously. 4, 13 ELISA for BAFF and APRIL. BAFF and APRIL serum concentrations were analyzed by commercial ELISA (R&D Systems) according to the manufacturer's instructions.
Immunoglobulin levels. Serum concentrations for IgG,
IgM, and IgA were determined by routine turbimetry (Olympus AU 2700) according to manufacturer's instructions.
RESULTS Patient characteristics and previous treat-
ments. All data are summarized in tables 1 and 2.
Treatment efficacy of rituximab. Monotherapy with rituximab resulted in a reduction of relapse rates in 8 of 10 patients and was more effective than the respective previous treatment ( figure 1, table 2 ). Three patients experienced a relapse after reappearance of B cells ( figure 2, A and B ). 14 Patient 4 did not respond to rituximab 15 ; combined treatment with methotrexate led to moderate reduction of the relapse rate (table 2, figure 2C ).
Adverse events. Adverse events are summarized in table 1. One patient died of cardiovascular failure 3 days after the second infusion of rituximab.
B-cell counts. B cells became undetectable in 9 of 10 patients within 14 days after the first dose. Time of B-cell repopulation varied interindividually (table 1) . After 3 patients experienced a relapse shortly after reappearance of B cells, rituximab was given at fixed intervals every 6 to 9 months (figure 2). This led to improved stabilization of NMO.
Immunoglobulin isotypes. Immunoglobulin isotype levels decreased only in patient 3 (after the third rituximab treatment) and patient 6 during rituximab therapy. Both had infections during rituximab therapy. After plasma exchange, all immunoglobulin isotypes transiently decreased but subsequently returned to normal despite therapy with rituximab.
AQP4-ab. AQP4-ab titer did not decline significantly during treatment and did not consistently correlate with disease activity (figure e-1 on the Neurology ® Web site at www.neurology.org).
B-cell-fostering cytokines. Baseline BAFF but not APRIL concentrations were significantly higher in patients with NMO as compared to healthy controls ( figure 3 ). BAFF increased significantly after the first course of rituximab. Application of rituximab at shorter intervals was accompanied by a lasting increase of BAFF (figures e-1 and e-2). DISCUSSION We report a prospective long-term follow-up of 10 patients with NMO who were repeatedly treated with rituximab. This treatment led to a reduction of relapse rates which was more pronounced when B cells were below detection levels. Comparable to recent reports, immunomodulatory therapies were less effective than immunosuppressants. 16 Safety of repeated rituximab administration was acceptable given the clinical severity of NMO. The death of one patient is presumably not treatmentrelated since cardiovascular failure has not been observed in patients treated for hematologic or rheumatic diseases. Since 2 patients developed concomitant infections (recurrent VZV infection, pneumonia) with a mild decrease of immunoglobulin levels, patients with decreased immunoglobulins should be monitored closely or even substituted with Up to 5 consecutive courses of rituximab were given. One course of rituximab (2 times 1 g 2 weeks apart) is indicated by arrows, relapses are indicated by triangles. Patient 4 did not respond to rituximab monotherapy; patient 1 died a few days after the first course. All other patients were stable when B cells were depleted completely. All their relapses were associated with B-cell reappearance. Dotted line ϭ methotrexate.
immunoglobulins. In our patients, relapses occurred after reappearance of B cells. This is in line with recent observations in patients with MS who had increased disease activity 9 -10 months after rituximab treatment just after reappearance of B cells. 17 Presumably even small numbers of B cells may trigger disease activity. This is strengthened by one study in patients with rheumatoid arthritis which showed a strong correlation of the clinical response and extent of B-cell depletion after rituximab as measured by highly sensitive FC analysis. 18 Therefore, such FC analysis might be useful for B-cell investigations in patients with NMO treated with rituximab. Based on our observations that most patients stabilized during phases of complete B-cell depletion, one should consider readministration of rituximab at fixed intervals of 6 -9 months, or immediately after B-cell reappearance detected by monthly performed highly sensitive FC. The pathogenetic role of AQP4-ab in NMO was recently demonstrated by several groups who could induce NMO-like disease in animals after injection of NMO IgG. 4, 5, 19 However, data on correlations between AQP4-ab titers and disease activity of patients with NMO are inconsistent. 6, 7, 20 In our observation, AQP4-abs increased during relapses but there were also significant increases during times when patients did not show any clinical disease activity. AQP4-ab did not decline consistently after repeated courses of rituximab. Like in other autoimmune diseases, the influence of rituximab on antibody titers is controversial. 21, 22 While rituximab effectively depletes CD20ϩ B cells from blood and CSF, [23] [24] [25] [26] [27] it does not eliminate plasma cells in the bone marrow, and therefore presumably has few effects on preexisting antibodies. 28 This may explain the lack of correlation between AQP4-ab titers and clinical disease activity in our study, indicating that other mechanisms beyond antibody reduction may contribute to clinical stabilization. These include inhibition of B-cell/Tcell interactions, increase of regulatory T cells, decrease of CD20ϩ cells with reduction of proinflammatory cytokines, 29 and modulation of the T-cell compartment. 30, 31 Elevation of BAFF serum concentrations in patients with NMO has recently been observed, 32 in contrast to MS. 33 Since BAFF is the key molecule supporting differentiation and survival of B cells and immunoglobulin production, increased BAFF supports the pivotal role of B cells and humoral immunity in NMO. As reported in other diseases, BAFF but not APRIL serum concentrations increased after rituximab therapy, 34, 35 but this was neither a prognostic nor a therapeutic marker in our cohort. Our data indicate that repeated application of rituximab is an emerging therapeutic option for patients with NMO as a second-line therapy. Additional investigations are needed to address the potential role of early treatment (e.g., after the first relapse).
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